MHRA Publishes Eleven Device Field Safety Notices in One Week in Mid-October 2026: Anaesthesia Systems, Interventional X-ray Systems and a Venous Stent in the Same Batch

Eleven Notices, Eleven Manufacturers, Devices Spanning Anaesthesia, Imaging and Implants

On 19 October 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) updated its weekly Field Safety Notice (FSN) list on GOV.UK, covering the period 12 to 16 October 2026. The list contains 11 FSNs from 11 manufacturers. The page carries a publication date of 19 October and a list issue date of 12 October; neither of these is the actual issue date of any individual notice, as explained below.

The most immediate observation is the breadth of device types covered. In anaesthesia, the list includes the Flow-i C20, C30 and C40 and the Flow-c and Flow-e anaesthesia systems from Maquet Critical Care AB (5 October). In imaging, it includes the Azurion interventional fluoroscopy X-ray systems from Philips Medical Systems Nederland B.V., models 722063 through 722285 (6 October). In implants, it includes the Abre venous self-expanding stent system from Medtronic (October; MHRA reference 2026/009/024/601/083).

In vitro diagnostics account for two entries. The Abbott i-STAT hs-TnI cartridge is listed under the product category troponin T / troponin I in vitro diagnostic reagent (October). The Beckman Coulter notice carries an issue date of 21 September, and the page places the specific product information in "Section 8", which must be confirmed against the manufacturer's original notice. Troponin is a key triage marker in emergency chest pain pathways, and where an IVD reagent is associated with a potential result bias, the volume of historical samples a hospital may need to review is typically substantial.

Several further entries are easily overlooked:

• ConvaTec — ESENTA Stomahesive Paste, categorised as a peristomal / wound dressing (October).
• Liko AB — Likorall overhead patient lift, covering a long series of models between 3121001 and 3124050 (7 October).
• American Orthodontics — orthodontic metal devices, covering all models (25 September).
• Freistihl Tischlerei GmbH — "Lisa", separately flagged as Urgent Safety Information (9 October).
• Cambridge Brain Sciences (trading as Creyos) — Creyos, with the earliest issue date in the batch, 5 August.
• NOxBOX — NOxBOXi nitric oxide delivery system (5 October).

Batch Dates Are Not the Trigger Date

The issue dates of these 11 notices run from 5 August through October, yet all appear in the same list for the week of 12 to 16 October. This confirms that the MHRA weekly list is a batch of notices published on GOV.UK during that week, not a set of notices issued during that week. Some notices may already have been executed by the manufacturer for one or two months before they appear on the regulator's public list.

For manufacturers this has two consequences. Waiting for the regulatory list to confirm whether something has happened is already too late; the real starting point is the original FSN received directly. And when monitoring comparable products, sorting by the batch date of the weekly list will produce a distorted timeline — the correct reference is the issue date on each individual notice.

MHRA's Requirements for FSNs Are Highly Specific

The MHRA guidance for manufacturers (published 20 May 2020, updated 16 June 2025 and aligned with the 2024 amendments to the post-market surveillance regulations) sets out the FSN content requirements as hard items:

• The title must read "Urgent FIELD SAFETY NOTICE" together with the trade name, and must include identification of the Field Safety Corrective Action (FSCA) and the type of action.
• Device identification must go down to model, lot or serial number, and must include the UDI where one exists.
• The body must clearly describe the defect or failure and the resulting hazard and risk.
• Actions required of the user must be given with a completion deadline.
• The notice must end with a confirmation reply form and must name a specific contact — the UK-based manufacturer, the UK Responsible Person (UKRP) or the Northern Ireland authorised representative.

The guidance also addresses two common errors. Manufacturers should not withhold an FSN while waiting for root cause analysis; they may issue the notice first and follow up with a supplementary notice. Notices must not downplay risk and must not contain product promotional content.

Traceability Remains the Manufacturer's Responsibility

The guidance is direct on traceability: contracts with distributors must include record-keeping requirements that allow tracing down to the end user. If a distributor is unwilling to provide customer lists, the contract should require the distributor to provide that information directly to the MHRA on request. Responsibility for ensuring the information reaches end users always remains with the manufacturer.

This is not new for companies active in the UK market, but every published list is a useful prompt for self-checking. A notice that receives no acknowledgements has, in effect, not been issued.

What Hospitals and Manufacturers Should Do on Receipt

Hospital actions

• Check affected model, lot and serial numbers against inventory.
• Quarantine or withdraw the affected devices from use as instructed.
• Review historical results or follow up patients as required by the notice — particularly for implants and IVDs.
• Return the acknowledgement form to the manufacturer and retain an internal record of the communication.

Manufacturer actions

• Confirm whether the affected product entered the UK market, in what quantity, and to which customers.
• Confirm whether the UK Responsible Person has been synchronised.
• Check that the deadlines stated in the notice match actual execution progress.
• Assess whether separate action is required for the same models in the EU and other markets.

Any gap in these items is likely to be recorded in a subsequent inspection.

Sources and Scope of Verification

Sources: MHRA, Field Safety Notices: 12 to 16 October 2026, published 19 October 2026, https://www.gov.uk/drug-device-alerts/field-safety-notices-12-october-2026-to-16-october-2026; MHRA, Field safety notices: guidance for manufacturers, published 20 May 2020 and updated 16 June 2025, https://www.gov.uk/guidance/effective-field-safety-notices-fsns-guidance-for-manufacturers-of-medical-devices.

Verification scope and access date: both pages were accessed on 27 October 2026 to check manufacturer names, product names, issue dates and MHRA references in the list, and the guidance statements on FSCA execution, required FSN content, traceability and distributor contract requirements. The specific product information for the Beckman Coulter entry is carried in "Section 8" of the manufacturer's original notice and has not been itemised here. The specific failure causes and required actions for each notice are governed by the manufacturer's original documents.

Applicability statement: this article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. The content of the list may change with subsequent official updates; the official texts prevail.

AIMEILI Regulatory Interpretation

The weekly list is a publication artefact, not a compliance clock

The most important structural point in this batch is the mismatch between list date and issue date. The 11 notices span 5 August to October, yet appear under a single mid-October week. Companies that build surveillance timelines from the weekly list will systematically misdate events, and may conclude that a competitor's action was newer or older than it actually was. A rigorous competitor and post-market watch should key on the issue date and MHRA reference of each individual notice, with the weekly list treated only as a discovery channel.

FSN quality has become an inspection artefact

The MHRA guidance converts the FSN from a communication into a structured document with mandatory elements: the prescribed title, FSCA identification and action type, identification down to lot or serial number with UDI where available, a stated hazard and risk, user actions with deadlines, an acknowledgement form and a named UK contact. Notices that omit the acknowledgement mechanism or name only a non-UK contact are a recurring weakness. So is the practice of holding a notice pending root cause analysis, which the guidance explicitly discourages in favour of a notice followed by a supplement.

The UKRP and distributor chain is where most gaps appear

The guidance allocates end-to-end traceability to the manufacturer, not the distributor. For non-UK manufacturers this means the UK Responsible Person must be in the distribution chain from the outset, not added at the point of a notice, and distributor agreements must contain enforceable record-keeping and, where necessary, direct-to-regulator disclosure obligations. In practice, the notices most likely to produce incomplete acknowledgement rates are those routed through multi-tier distributors or covering large model ranges — the Liko Likorall series and the all-model American Orthodontics entry in this batch are structurally exposed to this risk.

IVD and implant notices carry the longest look-back

The Abbott i-STAT hs-TnI and Medtronic Abre entries sit in the two categories where a notice triggers retrospective review of results or patient follow-up. The operational burden falls on hospitals, but the manufacturer's obligations — timely distribution, documented acknowledgement, and consistent action across markets — determine whether the field action can be closed out defensibly.

Business Impact

• Surveillance timelines need recalibration. Teams tracking competitor field actions should re-key their records to the notice issue date, or risk drawing the wrong conclusions about the timing, frequency and severity of actions in their device category.
• Distributor contracts warrant review. Agreements covering the UK should be checked for traceability-to-end-user clauses and for a mechanism obliging the distributor to provide customer information directly to the MHRA where requested. Absent these clauses, the manufacturer retains an obligation it cannot discharge.
• Acknowledgement rates are the practical measure of a field action. A notice distributed without returned acknowledgements leaves the manufacturer unable to demonstrate that the safety information reached users — the precise finding that escalates in an inspection.
• Notices should not wait on root cause analysis. Manufacturers holding a notice pending investigation should proceed with an initial FSN and follow up with a supplement, consistent with MHRA guidance.
• Multi-market consistency needs checking. Where a UK FSN has been issued, the same model range may require separate assessment and action in the EU and other jurisdictions; inconsistency between markets is visible to regulators and to customers.
• Model ranges as a risk factor. Notices covering long model series or all-model ranges multiply the identification and acknowledgement workload; pre-built model and UDI registers materially shorten response time.